Report of the 2nd Chagas Drug Discovery Consortium meeting, held on 3 November 2010; Atlanta GA, USA.
Chagas disease is an infectious disease with the highest impact in Latin America and a growing worldwide problem. Chagas disease is the result of long-term, persistent infection with the protozoan parasite Trypanosoma cruzi. The current therapies for treating T. cruzi infection and thus preventing Chagas disease often have adverse effects, unpredictable efficacy and require long courses of treatment. Development of new therapies has been very limited, in part due to lack of interest but also as a result of poor support and inappropriate models for discovering and evaluating candidate drugs. The Chagas Drug Discovery Consortium (CDDC) was created with funding from the US National Institutes of Health to help address some of these issues. The goals of the CDDC are to discover and evaluate new candidate drugs and develop rigorous assays of drug efficacy. This report summarizes the second meeting of the CDDC in November 2010.
University of Georgia, Center for Tropical and Emerging Global Diseases ,  Department of Cellular Biology ,  Athens, 500 D.W Brooks Dr. S310 Coverdell Center, GA 30602 ,  USA   +1 706 542 3378 ;  +1 706 542 3582 ;  tarleton@cb.uga.edu.
Juan M
JM
Bustamante
Hea Jin
HJ
Park
Rick L
RL
Tarleton